Healthcare apparel company Figs (NYSE:FIGS) announced better-than-expected revenue in Q3 CY2025, with sales up 8.2% year on year to $151.7 million. Its non-GAAP profit of $0.05 per share was significantly above analysts’ consensus estimates. Is now the time to buy FIGS? Find out in our full research report (it’s free for active Edge members). Figs (FIGS) Q3 CY2025 Highlights: Revenue: $151.7 million vs analyst estimates of $142.5 million (8.2% year-on-year growth, 6.4% beat) Adjusted EPS: $0.05 vs ana ...

Core Insights - Figs (FIGS) is valued at $1.33 billion and operates as a direct-to-consumer healthcare apparel and lifestyle brand, offering a range of products including scrubs, lab coats, activewear, and masks [1] - The stock has shown strong technical momentum, reaching a two-year high of $8.24 on October 22, and has gained 30% over the past year [4][3] Company Overview - Figs designs and sells healthcare apparel and non-scrub offerings, including sports bras, performance leggings, and loungewear, primarily through its website and mobile app [1] - The company has a 100% "Buy" technical rating from Barchart, indicating strong market confidence [4][5] Stock Performance - Since the Trend Seeker "Buy" signal was issued on October 15, the stock has appreciated by 5.28% [2] - Figs has achieved 9 new highs and a 17.25% gain in the last month, with a current trading price of $8.11 and a 50-day moving average of $7.09 [5] - The Relative Strength Index (RSI) is at 71.24, suggesting the stock is in a strong upward trend [5]